PMGMU — Priveterra Acquisition Share Price
Last trade - 00:00- $82.21m
- $81.91m
- 45
- 11
- 57
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.01 | ||
| Price to Tang. Book | 6.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.42% | ||
| Return on Equity | 2.33% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -29.62 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with a focus on the neurosciences market. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It has completed Phase II clinical study of ABP-450 for the treatment of cervical dystonia and has an ongoing Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- November 17th, 2020
- Public Since
- February 9th, 2021
- No. of Shareholders
- 3
- No. of Employees
- 3
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 8,902,272
- Address
- 300 Se 2Nd Street, Suite 600, FORT LAUDERDALE, 33301
- Web
- https://aeonbiopharma.com/
- Phone
- +1 4078081335
- Auditors
- WithumSmith Brown PC
Similar to PMGMU
10X Capital Venture Acquisition II
NASDAQ Capital Market
10X Capital Venture Acquisition II
NASDAQ Capital Market
1Sharpe Acquisition
NASDAQ Capital Market
26 Capital Acquisition
NASDAQ Capital Market
26 Capital Acquisition
NASDAQ Capital Market
FAQ
As of Today at 01:18 UTC, shares in Priveterra Acquisition are trading at $11.10. This share price information is delayed by 15 minutes.
Shares in Priveterra Acquisition last closed at $11.10 and the price had moved by +12.69% over the past 365 days. In terms of relative price strength the Priveterra Acquisition share price has underperformed the S&P500 Index by -1.85% over the past year.
There is no consensus recommendation for this security.
Find out morePriveterra Acquisition does not currently pay a dividend.
Priveterra Acquisition does not currently pay a dividend.
Priveterra Acquisition does not currently pay a dividend.
To buy shares in Priveterra Acquisition you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $11.10, shares in Priveterra Acquisition had a market capitalisation of $82.21m.
Here are the trading details for Priveterra Acquisition:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PMGMU
Based on an overall assessment of its quality, value and momentum Priveterra Acquisition is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Priveterra Acquisition. Over the past six months, its share price has underperformed the S&P500 Index by -1.88%.
As of the last closing price of $11.10, shares in Priveterra Acquisition were trading +11.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Priveterra Acquisition PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Priveterra Acquisition's directors